Autolus Therapeutics (NASDAQ:AUTL) Issues Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) released its earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10), Zacks reports. During the same quarter in the previous year, the business earned ($0.26) earnings per share.

Autolus Therapeutics Trading Down 8.5 %

Shares of Autolus Therapeutics stock traded down $0.28 during trading on Thursday, reaching $3.01. 2,578,474 shares of the company were exchanged, compared to its average volume of 1,436,413. Autolus Therapeutics has a twelve month low of $2.98 and a twelve month high of $7.45. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $800.94 million, a price-to-earnings ratio of -2.49 and a beta of 2.04. The business has a 50-day moving average price of $3.92 and a 200-day moving average price of $3.99.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.